– Motilent’s clinically-validated AI software has received 510k clearance from the US FDA
– Currently, 62 million people in the US are diagnosed with a digestive disorder annually[1], causing an ever-growing burden on healthcare services globally
– Almost $136BN is spent on GI therapies[2] annually but some drugs, e.g. those used in Inflammatory Bowel Disease, have a 60% failure rate within 1 year. It can take months or years to confirm if a therapy is no longer working for a patient.
– New collaboration with AI-powered solutions provider Nuance Communications will allow US healthcare clinics using innovative GIQuant software to accurately measure intestinal motility and treatment response using AI medical image analysis